secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eton Pharmaceuticals, Inc. (ETON)
CIK:        0001710340
Form:       8-K
Filed at:   2023-06-15T23:59:59+00:00
Accession:  0001493152-23-021435
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Eton enters stalking horse bid to acquire Wellstat assets for $37M; sells royalty interests for $5.5M
--------------------------------------------------------------------------------

- Eton named stalking horse bidder to acquire commercial assets of Wellstat Therapeutics & Biologics for $37M via bankruptcy auction.
- Closing is uncertain and subject to the auction process; Eton has cash on hand and committed financing to complete the deal if successful.
- Eton amended its 2020 Asset Purchase Agreement with Azurity Pharmaceuticals, agreeing to sell back royalty interests for $5.5M in cash.
- The $5.5M from Azurity provides near-term liquidity; proceeds are included in Eton's available funds for the potential Wellstat acquisition.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710340/000149315223021435/0001493152-23-021435-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710340/000149315223021435/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-021435

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer